Clinical Trials Browser

NIH × Central Nervous System Neoplasms × pazopanib × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma